Published in J Clin Invest on December 01, 1973
Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med (1975) 7.87
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G. J Exp Med (1975) 3.80
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med (1981) 2.33
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism. J Exp Med (1974) 2.22
The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. J Exp Med (1978) 1.56
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med (1988) 1.48
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Malignant lymphomas--a conceptual understanding of morphologic diversity. A review. Am J Pathol (1979) 1.30
Complement receptor subtypes C3b and C3d in lymphatic tissue and follicular lymphoma. Br J Cancer (1978) 1.27
Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells. Clin Exp Immunol (1982) 1.26
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A (1985) 1.16
Bone marrow-derived lymphoid cell lines from patients with agammaglobulinemia. J Clin Invest (1978) 1.07
Immune complexes in human diseases: a review. Am J Pathol (1980) 1.05
A possible role for polymorphonuclear leucocytes in the defence against recrudescent herpes simplex virus infection in man. Immunology (1978) 1.01
Immunologic diagnosis and monitoring of human acute leukemias: a review. Am J Pathol (1981) 0.90
The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo. J Exp Med (2003) 0.88
Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus. Infect Immun (1983) 0.85
Activated guinea-pig C3 and the immune adherence receptor (a complement receptor) on cell membranes. Immunology (1975) 0.85
T-cell and B-cell identification in the diagnosis of lymphoproliferative disease. A review. Am J Pathol (1977) 0.84
BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology (1988) 0.84
Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med (1987) 0.84
Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors. Infect Immun (1985) 0.80
Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes. J Clin Invest (1977) 0.76
Purification and characterization of human bone marrow lymphocyte subpopulations: evidence for the existence of an alloreactive immature T cell. Clin Exp Immunol (1981) 0.75
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol (1967) 3.86
Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5. J Exp Med (1969) 2.38
Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement. J Exp Med (1969) 2.30
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharide. J Exp Med (1973) 2.25
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med (2000) 5.83
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood (1973) 4.99
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell (1997) 4.65
Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (1989) 4.08
A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A (1975) 3.97
Migration of Plasmodium sporozoites through cells before infection. Science (2001) 3.89
Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science (1980) 3.71
Ca++-dependent binding of antigen-19 S antibody complexes to macrophages. J Immunol (1969) 3.70
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med (1976) 3.68
Complement receptor is an inhibitor of the complement cascade. J Exp Med (1981) 3.65
Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (1987) 3.62
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med (1982) 3.26
Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 3.24
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci (1998) 3.16
Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med (1983) 3.07
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Mechanism of binding of soluble immune complexes to lymphocytes. Cell Immunol (1973) 2.93
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell (1992) 2.78
Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. Nature (1982) 2.76
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med (1993) 2.60
Structure of the plasmodium knowlesi gene coding for the circumsporozoite protein. Cell (1983) 2.60
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science (1987) 2.59
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature (1997) 2.49
Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A (2001) 2.46
Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45
Conservation of a gliding motility and cell invasion machinery in Apicomplexan parasites. J Cell Biol (1999) 2.43
The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med (1976) 2.41
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science (1985) 2.41
Research toward malaria vaccines. Science (1986) 2.40
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Tissue localization of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. Proc Natl Acad Sci U S A (1970) 2.29
Complement-dependent release of immune complexes from the lymphocyte membrane. J Exp Med (1973) 2.27
Stage-specific surface antigens expressed during the morphogenesis of vertebrate forms of Trypanosoma cruzi. Exp Parasitol (1987) 2.25
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest (1978) 2.24
Receptors for immune complexes on lymphocytes. Adv Immunol (1974) 2.23
Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene (2007) 2.22
Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol (1987) 2.19
Induced neuronal differentiation of human embryonic stem cells. Brain Res (2001) 2.12
Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol (1985) 2.09
Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother (1998) 2.07
A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell (1991) 2.04
Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med (1981) 2.02
Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience (2003) 2.02
The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J Exp Med (1979) 1.97
Selective phagocytic paralysis induced by immobilized immune complexes. J Exp Med (1975) 1.96
Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci (2000) 1.93
Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ (1979) 1.92
Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein. Nature (1983) 1.90
Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature (1983) 1.90
Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol (1994) 1.89
Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron (1997) 1.89
Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med (1986) 1.88
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A (1985) 1.87
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
Complement as a regulator of interactions between immune complexes and cell membranes. J Immunol (1974) 1.83
Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A (1982) 1.82
Bone marrow origin of complement-receptor lymphocytes. Eur J Immunol (1971) 1.80
Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology. Transplant Rev (1976) 1.80
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
Specificity of the antibodies produced by single cells following immunization with antigens bearing two types of antigenic determinants. J Exp Med (1967) 1.75
Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J Exp Med (1994) 1.75
Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene (2010) 1.72
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci (2001) 1.66
The exit of Trypanosoma cruzi from the phagosome is inhibited by raising the pH of acidic compartments. J Exp Med (1990) 1.64
Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells. J Immunol (1982) 1.63
Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci (1999) 1.59
Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci U S A (2001) 1.59
Synthetic peptide vaccine confers protection against murine malaria. J Exp Med (1987) 1.58
Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol (1999) 1.55
Purificaiton and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein). J Exp Med (1977) 1.50
Attachment of Trypanosoma cruzi to mammalian cells requires parasite energy, and invasion can be independent of the target cell cytoskeleton. Infect Immun (1991) 1.50
A glycan-phosphatidylinositol-specific phospholipase D in human serum. Science (1987) 1.50
Characterization of a novel trypanosome lytic factor from human serum. Infect Immun (1999) 1.49
The large difference in infectivity for mice of Plasmodium berghei and Plasmodium yoelii sporozoites cannot be correlated with their ability to enter into hepatocytes. Mol Biochem Parasitol (1996) 1.47
Dynamic relocalization of histone MacroH2A1 from centrosomes to inactive X chromosomes during X inactivation. J Cell Biol (2000) 1.47
Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med (1990) 1.46
Immunoglobulin-bearing and complement-receptor lymphocytes constitute the same population in human peripheral blood. J Clin Invest (1976) 1.46